Eicosapentaenoic Acid Improves Endothelial Nitric Oxide Bioavailability Via Changes in Protein Expression During Inflammation
Open Access
- 16 July 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (14) , e034076
Abstract
Background: Endothelial cell (EC) dysfunction involves reduced nitric oxide (NO) bioavailability due to NO synthase uncoupling linked to increased oxidation and reduced cofactor availability. Loss of endothelial function and NO bioavailability are associated with inflammation, including leukocyte activation. Eicosapentaenoic acid (EPA) administered as icosapent ethyl reduced cardiovascular events in REDUCE‐IT (Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial) in relation to on‐treatment EPA blood levels. The mechanisms of cardiovascular protection for EPA remain incompletely elucidated but likely involve direct effects on the endothelium. Methods and Results: In this study, human ECs were treated with EPA and challenged with the cytokine IL‐6 (interleukin‐6). Proinflammatory responses in the ECs were confirmed by ELISA capture of sICAM‐1 (soluble intercellular adhesion molecule‐1) and TNF‐α (tumor necrosis factor‐α). Global protein expression was determined using liquid chromatography–mass spectrometry tandem mass tag. Release kinetics of NO and peroxynitrite were monitored using porphyrinic nanosensors. IL‐6 challenge induced proinflammatory responses from the ECs as evidenced by increased release of sICAM‐1 and TNF‐α, which correlated with a loss of NO bioavailability. ECs pretreated with EPA modulated expression of 327 proteins by >1‐fold ( P P <0.05). Conclusions: These direct actions of EPA on EC functions during inflammation may contribute to its distinct cardiovascular benefits.Keywords
This publication has 86 references indexed in Scilit:
- Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate ContinuesCurrent Atherosclerosis Reports, 2022
- Glycyrrhizin Prevents Hemorrhagic Transformation and Improves Neurological Outcome in Ischemic Stroke with Delayed Thrombolysis Through Targeting Peroxynitrite-Mediated HMGB1 SignalingTranslational Stroke Research, 2019
- Icosapent Ethyl Effects on Fatty Acid Profiles in Statin-Treated Patients With High Triglycerides: The Randomized, Placebo-controlled ANCHOR StudyCardiology and Therapy, 2019
- Pharmacokinetics of eicosapentaenoic acid in plasma and red blood cells after multiple oral dosing with icosapent ethyl in healthy subjectsClinical Pharmacology in Drug Development, 2013
- Icosapent Ethyl, a Pure Ethyl Ester of Eicosapentaenoic Acid: Effects on Circulating Markers of Inflammation from the MARINE and ANCHOR StudiesAmerican Journal of Cardiovascular Drugs, 2013
- Endothelium2013
- Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study)The American Journal of Cardiology, 2012
- Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] Trial)The American Journal of Cardiology, 2011
- Endothelium-derived Vasoactive Factors and Hypertension: Possible Roles in Pathogenesis and as Treatment TargetsCurrent Hypertension Reports, 2010
- Eicosapentaenoic acid as a modulator of inflammationBiochemical Pharmacology, 1986